Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress

The findings were published in the peer-reviewed journal Diabetes, Obesity and Metabolism.

Rhea-AI Summary

Omada Health (OMDA) will present research showing greater weight loss among its GLP-1 Care Track members than usual-care participants.

The 12-week comparative study followed 245 adults with obesity who had started GLP-1 weight-loss medication within the previous eight weeks: 151 Omada members and 94 receiving usual care. Average weight loss was 6.0% versus 3.3% of starting body weight. Body fat percentage fell by −3.3% versus −1.6%, while muscle mass percentage increased by +0.6% versus +0.2%. Omada members also reported greater improvements in well-being, physical functioning and confidence in losing weight. Their depression and anxiety symptoms fell roughly 30%, significantly more than in usual care.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointAverage weight loss reached 6.0% versus 3.3% of starting body weight with usual care after 12 weeks.
• Minor pointBody fat percentage fell −3.3% versus −1.6% with usual care after 12 weeks.
• Minor pointMuscle mass percentage increased +0.6% versus +0.2% with usual care after 12 weeks.
• Minor pointDepression and anxiety symptoms fell roughly 30%, significantly more than with usual care after 12 weeks.
• Minor pointMembers reported greater improvements in well-being, physical functioning and weight-loss confidence than usual-care participants.
• Minor pointStudy findings were published in the peer-reviewed journal Diabetes, Obesity and Metabolism.

Negative

• None.

Key Figures

Study participants: 245 adults Weight loss: 6.0% vs. 3.3% Body fat percentage change: −3.3% vs. −1.6% +1 more

Study participants

245 adults

Adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks

Weight loss

6.0% vs. 3.3%

12 weeks; Omada GLP-1 Care Track vs. usual care

Body fat percentage change

−3.3% vs. −1.6%

12 weeks; Omada GLP-1 Care Track vs. usual care

Muscle mass percentage change

+0.6% vs. +0.2%

12 weeks; Omada GLP-1 Care Track vs. usual care

Key Terms

glp-1, bioelectrical impedance, resting metabolic rate

3 terms

glp-1 medical

"adults with obesity who had started a GLP-1 for weight loss"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

bioelectrical impedance technical

"Participants measured body composition at home using bioelectrical impedance scales."

A measure of how much the body's tissues resist or conduct a small, safe electrical current passed through the body; devices use that resistance (impedance) along with equations to estimate body composition such as fat mass, lean mass and body water. The reading depends on current frequency, electrode placement and the person's hydration and recent activity, so results are estimates rather than direct measurements and can vary with measurement conditions.

resting metabolic rate medical

"reductions in resting metabolic rate"

Resting metabolic rate (RMR) is the amount of energy, measured in calories, that a person’s body uses per day while at rest to support basic physiological functions such as breathing, circulation, body temperature regulation, and cell repair. It is estimated by measuring oxygen consumption and carbon dioxide production or by applying validated equations that use factors like age, sex, weight and height; RMR is usually slightly higher than basal metabolic rate (BMR) because RMR is measured under less strict conditions and does not require the full fasting, sleep and controlled-environment protocol that defines BMR.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The oral presentation will share results from a 12-week comparative study showing that Omada GLP-1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controls

SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Management Congress (WOC 2026) in Boston showing that members of its GLP-1 Care Track lost more weight and experienced greater improvements in body composition than GLP-1 users receiving usual care. The findings were recently published in the peer-reviewed journal Diabetes, Obesity and Metabolism.¹

GLP-1 medications can produce rapid weight loss,² but lean mass can account for 30% or more of the weight lost.^3,4 Lean mass is critical for overall health, as losing lean mass may contribute to reductions in resting metabolic rate⁵, impaired physical function and greater susceptibility to weight regain,⁶ as well as an increased risk for sarcopenia,⁷ frailty, and bone loss.^6,8 While exercise and resistance training are known to be effective strategies for increasing fat loss while protecting lean mass,¹ much less is known about whether virtual care programs can improve body composition outcomes for people taking GLP-1 medications.

The study followed 245 adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks.¹ Of those, 151 participated in Omada's GLP-1 Care Track and 94 received usual care, which could include medication alone or other, non-Omada lifestyle programs. More than a quarter (26%) of the usual care group reported using another lifestyle or wellness program during the study.¹

After 12 weeks, compared with the usual care group, Omada members on average:¹

• Lost more weight (6.0% of starting body weight vs. 3.3%)
• Reduced their body fat percentage by about twice as much (−3.3% vs. −1.6%)
• Saw a larger increase in muscle mass percentage (+0.6% vs. +0.2%)
• Reported greater improvements in well-being, physical functioning, and confidence in their ability to lose weight
• Saw depression and anxiety symptoms drop by roughly 30%, significantly more than the usual care group
  
  

The GLP-1 Care Track provides clinical support between doctor visits. Members work with a care team that includes a dedicated health coach, GLP-1-specific peer support groups, digital tools for meal logging and behavior tracking, and AI-powered nutrition support.¹ The program also includes access to an exercise specialist who provides a personalized exercise plan developed by a physical therapist. Participants measured body composition at home using bioelectrical impedance scales.

"GLP-1 care is about more than how much weight you lose. It’s about the quality of the weight loss, as losing too much muscle can make it harder to keep the weight off long-term," said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. "Too many people are left to manage side effects, exercise, and nutrition on their own once GLP-1 treatment starts. This study suggests that clinical support between doctor visits can help people achieve greater weight loss and better body composition, and protect their muscle mass.”

This study was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.

Omada Health’s Clinical Research Scientist, Lisa A. Stanton, PhD, will present "Improving GLP-1 Weight Loss Quality with a Virtual Lifestyle Companion Program" on Tuesday, October 20, 2026, at 3:20 PM ET during the Anti-Obesity Drugs & Emerging Therapies session at WOC 2026, held October 19-21.

Omada Health
Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

Media Contact
Rose Ramseth
press@omadahealth.com

1. Stanton LA, Naqvi JB, Devaraj SM, et al. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. Diabetes Obes Metab. 2026:1-12. doi:10.1111/dom.71152.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
3. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787. doi:10.1016/S2213-8587(24)00272-9
4. Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14(1):63. doi:10.1007/s13668-025-00649-w
5. Hopkins M, Gibbons C, Blundell J. Fat-free mass and resting metabolic rate are determinants of energy intake: implications for a theory of appetite control. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220213. doi:10.1098/rstb.2022.0213
6. Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-953. doi:10.1177/0148607114550189
7. Scheen AJ. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations. Diabetes Metab. 2025;52(1):101708. doi:10.1016/j.diabet.2025.101708
8. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Omada Health's GLP-1 Care Track study show about weight loss?

Omada members lost an average of 6.0% of starting body weight over 12 weeks, compared with 3.3% among usual-care participants. The comparative study included 151 Omada members and 94 usual-care participants, all adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks.

How did body composition change in Omada Health's GLP-1 study?

After 12 weeks, body fat percentage changed by −3.3% for Omada members versus −1.6% for usual-care participants, while muscle mass percentage increased by +0.6% versus +0.2%.

How was body composition measured in Omada Health's GLP-1 study?

Participants measured body composition at home using bioelectrical impedance scales, which estimate body composition using electrical signals.

What care did the comparison group receive in Omada Health's GLP-1 study?

The usual-care group could receive medication alone or other, non-Omada lifestyle programs. More than a quarter (26%) reported using another lifestyle or wellness program during the study.